The past decades IDA has been working together with several partners to ensure the delivery of essential anti-TB medication to high-burden countries. We have built an extensive TB portfolio over the years and gathered much knowledge about the nature of the disease and how to build sustainable networks and infrastructure that help eradicate this disease globally.

On behalf of Stop TB Partnership’s Global Drug Facility (GDF), IDA Foundation (IDA), the GDF- contracted procurement agent, invites all eligible suppliers to submit bids (ITB) for pretomanid tablets for the period until 31 December 2023.

On behalf of Stop TB Partnership’s Global Drug Facility (GDF), IDA Foundation (IDA), the GDF’s contracted procurement agent, invites all eligible suppliers to submit bids for ITB-IDA/GDF-MED/2022/1, for the supply of antituberculosis (TB) medicines.

Tuberculosis (TB) is one of the world’s most common and life threatening diseases, with over 95% of TB deaths occurring in low-and middle-income countries (LMICs). In 2019, an estimated 10 million people were diagnosed with TB worldwide and there are estimates that indicate that one third of the world’s population is infected with TB.

IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of Ethambutol 100mg dispersible tablets for the treatment of drug-sensitive forms of tuberculosis.

Just over a year after the start of the corona pandemic it is clear that covid-19 has had a devastating impact on the progress of existing tuberculosis (TB) programmes. For latent and progressive infectious diseases, such as TB, early diagnosis and treatment are essential.

IDA Foundation, on behalf of the Stop TB Partnership/The Global Drug Facility (GDF), is today launching an Invitation to Bid (ITB) for the supply of ANTI-TUBERCULOSIS MEDICINES AND RELATED PRODUCTS for the treatment of DRUG-RESISTANT FORMS of tuberculosis to eligible manufacturers.

On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.

As the Corona virus pandemic spreads around the globe, and all health care systems and governments seem to be engulfed with battling COVID-19, we realise it is more important than ever that we don’t lose sight of other existing health issues.

While coronavirus (COVID-19) dominates the news, we need to remember that another respiratory disease kills 1.5 million people per year: tuberculosis (TB). This is an opportunity to unite forces in the fight against TB and coronavirus.